Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.
2.

Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.

Seidenfeld J, Samson DJ, Aronson N, Albertson PC, Bayoumi AM, Bennett C, Brown A, Garber A, Gere M, Hasselblad V, Wilt T, Ziegler K.

Evid Rep Technol Assess (Summ). 1999 May;(4):i-x, 1-246, I1-36, passim. Review.

PMID:
11098244
[PubMed - indexed for MEDLINE]
Free Article
3.

Combined androgen blockade in advanced prostate cancer: looking back to move forward.

Chodak G, Gomella L, Phung de H.

Clin Genitourin Cancer. 2007 Sep;5(6):371-8. Review.

PMID:
17956709
[PubMed - indexed for MEDLINE]
4.

Nilutamide: an antiandrogen for the treatment of prostate cancer.

Dole EJ, Holdsworth MT.

Ann Pharmacother. 1997 Jan;31(1):65-75. Review.

PMID:
8997470
[PubMed - indexed for MEDLINE]
5.

Commentary on maximal androgen blockade in prostate cancer: a theory to put into practice?

Denis L.

Prostate. 1995 Nov;27(5):233-40. Review.

PMID:
7479390
[PubMed - indexed for MEDLINE]
6.

The role of antiandrogen monotherapy in the treatment of prostate cancer.

Anderson J.

BJU Int. 2003 Mar;91(5):455-61. Review.

PMID:
12603397
[PubMed - indexed for MEDLINE]
7.

Antiandrogen monotherapy: recommendations for the treatment of prostate cancer.

Sciarra A, Cardi A, Di Silverio F.

Urol Int. 2004;72(2):91-8. Review.

PMID:
14963347
[PubMed - indexed for MEDLINE]
8.

[First line therapy in the treatment of metastatic prostate cancer].

Sakai H, Kanetake H.

Gan To Kagaku Ryoho. 2003 Jan;30(1):43-9. Review. Japanese.

PMID:
12557704
[PubMed - indexed for MEDLINE]
9.

Antiandrogenic drugs.

McLeod DG.

Cancer. 1993 Feb 1;71(3 Suppl):1046-9. Review.

PMID:
8428326
[PubMed - indexed for MEDLINE]
10.

Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer.

Mahler C, Verhelst J, Denis L.

Clin Pharmacokinet. 1998 May;34(5):405-17. Review.

PMID:
9592622
[PubMed - indexed for MEDLINE]
11.

Monotherapy in advanced prostate cancer: an overview.

Baltogiannis D, Giannakopoulos X, Charalabopoulos K, Sofikitis N.

Exp Oncol. 2004 Sep;26(3):185-91. Review.

PMID:
15494685
[PubMed - indexed for MEDLINE]
12.

Are non-steroidal anti-androgens appropriate as monotherapy in advanced prostate cancer?

Boccon-Gibod L.

Eur Urol. 1998;33(2):159-64. Review.

PMID:
9519357
[PubMed - indexed for MEDLINE]
13.

Antiandrogens as monotherapy for prostate cancer.

Schröder FH.

Eur Urol. 1998;34 Suppl 3:12-7. Review.

PMID:
9854190
[PubMed - indexed for MEDLINE]
14.

Maximal androgen blockade for advanced prostate cancer.

Klotz L.

Best Pract Res Clin Endocrinol Metab. 2008 Apr;22(2):331-40. doi: 10.1016/j.beem.2008.01.004. Review.

PMID:
18471790
[PubMed - indexed for MEDLINE]
15.
16.

Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer.

Kolvenbag GJ, Iversen P, Newling DW.

Urology. 2001 Aug;58(2 Suppl 1):16-23. Review.

PMID:
11502439
[PubMed - indexed for MEDLINE]
17.

Maximum androgen blockade in 1996.

Boccon-Gibod L.

Eur Urol. 1996;30 Suppl 1:15-8; discussion 19-21. Review.

PMID:
8977985
[PubMed - indexed for MEDLINE]
18.

Clinical applications of antiandrogens.

Namer M.

J Steroid Biochem. 1988 Oct;31(4B):719-29. Review.

PMID:
2462132
[PubMed - indexed for MEDLINE]
19.

First-line treatment of metastatic prostate cancer. Androgen suppression for symptomatic disease.

[No authors listed]

Prescrire Int. 2013 Feb;22(135):48-51. Review.

PMID:
23444510
[PubMed - indexed for MEDLINE]
20.

Endocrine treatment of prostate cancer.

Tammela T.

J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95. Epub 2004 Dec 31. Review.

PMID:
15663992
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk